![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)
Advanced Healing Now Possible (OTC:DSCI)
Michael Vlaicu (September 1st, 2009) Writes:
Derma Sciences, Inc.
(Public, OTC:DSCI)
Derma Sciences is a truly unique and highly undervalued company within the micro-cap biomed space which currently targets a prescription drug market that is about 5x its present market cap. The company is developing a patented topical drug for accelerated healing and scar prevention and newly launched Advanced Wound Care products approaching $10M, including the highly received MEDIHONEY, and BIOGUARD, both of which have garnered tremendeous success and continue to increase sales annually. The real gem however lies within their DSC127 phase II pipeline drug. Derma Sciences reported that it continues to move forward with clinical trials of DSC127, which has the potential to be only the second approved drug on the market for accelerated wound healing, a market with over $100M in sales anually.
About
Derma Sciences, Inc. is a fully integrated manufacturer, marketer and
...
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.